tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

OKYO Stock Latest News

OKYO Pharma Advances OK-101 into Phase 2 Trials
Company AnnouncementsOKYO Pharma Advances OK-101 into Phase 2 Trials
16d ago
6K
OKYO
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
PremiumPress Releases
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
16d ago
OKYO
Okyo Pharma to initiate neuropathic corneal pain trial for OK-101
PremiumThe Fly
Okyo Pharma to initiate neuropathic corneal pain trial for OK-101
16d ago
OKYO
OKYO Pharma’s OK-101 Shows Promising Phase 2 Results
PremiumCompany Announcements
OKYO Pharma’s OK-101 Shows Promising Phase 2 Results
17d ago
6K
OKYO
OKYO Pharma Release Lacks Content
PremiumCompany Announcements
OKYO Pharma Release Lacks Content
17d ago
6K
OKYO
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
PremiumPress ReleasesOKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
17d ago
OKYO
Okyo Pharma announces new data from OK-101 Phase 2 trial
PremiumThe Fly
Okyo Pharma announces new data from OK-101 Phase 2 trial
17d ago
OKYO
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
PremiumPress Releases
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
3M ago
OKYO
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
PremiumPress Releases
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
4M ago
OKYO
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
PremiumPress Releases
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
4M ago
OKYO
Okyo Pharma price target raised to $7 from $6 at H.C. Wainwright
PremiumThe Fly
Okyo Pharma price target raised to $7 from $6 at H.C. Wainwright
4M ago
OKYO
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
PremiumPress Releases
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
4M ago
OKYO
Okyo announces OK-101 achieved statistical significance for pain reduction
PremiumThe FlyOkyo announces OK-101 achieved statistical significance for pain reduction
4M ago
OKYO
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
PremiumPress Releases
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
4M ago
OKYO
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
PremiumPress Releases
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
4M ago
OKYO
Okyo Pharma to release new data from Phase 2 dry eye disease trial
PremiumThe Fly
Okyo Pharma to release new data from Phase 2 dry eye disease trial
4M ago
OKYO
Okyo Pharma price target raised to $6 from $5 at H.C. Wainwright
PremiumThe Fly
Okyo Pharma price target raised to $6 from $5 at H.C. Wainwright
6M ago
OKYO
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
PremiumPress Releases
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
6M ago
OKYO
Okyo Pharma receives FDA approval of IND for OK-101
PremiumThe Fly
Okyo Pharma receives FDA approval of IND for OK-101
6M ago
OKYO
Okyo Pharma appoints Perez, Galor, Milner to Scientific Advisory board
PremiumThe FlyOkyo Pharma appoints Perez, Galor, Milner to Scientific Advisory board
6M ago
OKYO
Okyo Pharma price target raised to $5 from $4 at H.C. Wainwright
PremiumThe Fly
Okyo Pharma price target raised to $5 from $4 at H.C. Wainwright
7M ago
OKYO
Okyo Pharma’s OK-101 achieved statistical significance for two endpoints
PremiumThe Fly
Okyo Pharma’s OK-101 achieved statistical significance for two endpoints
7M ago
OKYO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >